Phase 1 Study OF CDC-501 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2006-09-28
Target enrollment:
Participant gender:
Summary
To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week
cycle in patients with solid tumors that are refractory after standard treatment.